⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252357 | 0.94 | — | — | |
| SCHEMBL609517 | 0.78 | CYP1A2 (0.32) | — | |
| SCHEMBL13135700 | 0.72 | — | — | |
| SCHEMBL14135957 | 0.69 | — | — | |
| SCHEMBL25919081 | 0.69 | — | — | |
| SCHEMBL541379 | 0.67 | — | — | |
| SCHEMBL2666674 | 0.67 | — | — | |
| SCHEMBL17199405 | 0.67 | CYP1A2 (0.31) | — | |
| SCHEMBL20749862 | 0.67 | CYP1A2 (0.31) | — | |
| SCHEMBL2667238 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2554540-A2 | 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | Novartis AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-8252931-B2 | Thiazolo[5,4-B]pyridine glucokinase activators | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-2298779-A1 | Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes | Novartis AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-7795257-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| EP-2221896-A1 | ORGANIC EL ELEMENT | Idemitsu Kosan Co., Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20080318948-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080312256-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| WO-2007041366-A1 | SULFONAMIDE DERIVATIVES AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041365-A2 | 3-CYCLYL-2- (4-SULFAMO YL-PHENYL) -N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |